Treatment with Brentuximab Vedotin Prior to Reduced Intensity Allogeneic HCT in Relapsed/Refractory HL


Treatment with Brentuximab Vedotin Prior to Reduced Intensity Allogeneic HCT in Relapsed/Refractory HL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/11/12)

Chen RW et al. Brentuximab vedotin (SGN-35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. Proc ASH 2011;Abstract 664.

Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.